Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 6/20 | 0.38 |
| ▸ | CDC25A | P30304 | 6/20 | 0.37 |
| ▸ | CDC25B | P30305 | 6/20 | 0.37 |
| ▸ | CDC25C | P30307 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BID | P55957 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5692438 | 0.83 | HCAR2 (0.39) | HCAR2HCAR3RARBMEN1ALDH1A1 | |
| SCHEMBL13727448 | 0.77 | NAAA (0.44) | ALDH1A1 | |
| SCHEMBL10768279 | 0.72 | MAPT (0.47) | ALDH1A1MAPT | |
| SCHEMBL5114405 | 0.71 | POLB (0.47) | ALDH1A1MAPTKMT2A | |
| SCHEMBL11822376 | 0.71 | GABRP (0.46) | HCAR2HCAR3RARBALDH1A1 | |
| SCHEMBL5691138 | 0.70 | NPSR1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL15894461 | 0.70 | RARB (0.43) | HCAR2HCAR3RARBMEN1ALDH1A1 | |
| SCHEMBL5701035 | 0.69 | HCAR2 (0.44) | HCAR2HCAR3RARBMEN1ALDH1A1 | |
| SCHEMBL8805901 | 0.69 | ALDH1A1 (0.44) | HCAR2HCAR3RARBALDH1A1MAPT | |
| SCHEMBL92739 | 0.69 | KCNH2 (0.46) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1309566-B1 | DIHYDROXYPYRIMIDINE CARBOXYLIC ACIDS AS VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-10-07 | — | — | EP | disclosed |
| EP-1309566-B1 | DIHYDROXYPYRIMIDINE CARBOXYLIC ACIDS AS VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-10-07 | — | — | EP | disclosed |
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | disclosed |
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7091209-B2 | Dihydroxypyridmidine carboxylic acids as viral polymerase inhibitors | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-7091209-B2 | Dihydroxypyridmidine carboxylic acids as viral polymerase inhibitors | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-7037908-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | disclosed |
| WO-2004096128-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004062613-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040106627-A1 | Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECULARE P ANGELETTI SPA (IT) | 2004-06-03 | — | — | US | disclosed |
| US-20040106627-A1 | Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECULARE P ANGELETTI SPA (IT) | 2004-06-03 | — | — | US | disclosed |
| EP-1309566-A1 | DIHYDROXYPYRIMIDINE CARBOXYLIC ACIDS AS VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2003-05-14 | — | — | EP | disclosed |
| EP-1309566-A1 | DIHYDROXYPYRIMIDINE CARBOXYLIC ACIDS AS VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002006246-A1 | DIHYDROXYPYRIMIDINE CARBOXYLIC ACIDS AS VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006246-A1 | DIHYDROXYPYRIMIDINE CARBOXYLIC ACIDS AS VIRAL POLYMERASE INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | DUT, CDK6, TYMS | HCAR2 1154/4885HCAR3 1183/4885RARB 1617/4885 |
| US-20040106627-A1 | Dihydroxypyrimidine carboxylic acids as viral polymerase inhibitors | DPYD, DUT, UMPS | HCAR2 1380/4885HCAR3 1848/4885RARB 1189/4885 |
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | HCAR2 4595/4885HCAR3 4518/4885RARB 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.